Comparing clinical and biochemical characteristics of febrile seizures in children with and without COVID-19: a retrospective study Authors: Nanxi Zhu, Ruming Ye, Fangyi Liu, Dan Li, Ying Lin, Wanting Li, Guanhong Wu, Deyi Zhuang, Xianghui Huang Published: 2024 ABSTRACT AbstractBackgroundTransmission of COVID-19 is now normalized. There is an association between it and increased incidence of febrile seizures in children. Exploring whether COVID-19 has a specific effect on the clinical and biochemical features of febrile seizures is critical for the development of clinical treatment and prevention strategies. This study is to compare the differences in clinical features, hematological features, and cerebrospinal fluid characteristics between COVID-19 and non-COVID-19 children with febrile seizures and to provide a new perspective for further exploring the impact of COVID-19 on the nervous system of children.MethodsThis was a retrospective case–control study. The cases included children with COVID-19 and non-COVID-19 febrile seizures admitted to Xiamen Children’s Hospital from December 2022 to December 2023. The age, gender, length of hospital stay, peak body temperature, presence or absence of other viral infections, hematological characteristics, and cerebrospinal fluid characteristics were compared between children with COVID-19 febrile seizures and non-COVID-19 febrile seizures.ResultsA total of 50 COVID-19 children with febrile seizures and 192 non-COVID-19 children with febrile seizures were enrolled in this study. Multivariate analysis showed that age (OR = 0.715, P = 0.031), blood urea nitrogen (OR = 0.454, P = 0.029), platelet count (OR = 0.987, P = 0.009) and magnesium ion concentration (OR = 0.109, P < 0.001) were negatively correlated with COVID-19 febrile seizures. Albumin (OR = 1.840, P < 0.001) was positively correlated. The concentration of potassium ion in cerebrospinal fluid (OR = 0.334, P = 0.012) was negatively correlated with COVID-19 febrile seizures, and the concentration of sodium ion (OR = 4.383, P = 0.022) was positively correlated with COVID-19 febrile seizures.ConclusionThere were differences in age, blood urea nitrogen, platelet count, magnesium ion concentration, albumin, potassium ion concentration in cerebrospinal fluid, and sodium ion concentration in the cerebrospinal fluid between children with COVID-19 febrile seizures and non-COVID-19 febrile seizures. This study may provide valuable insights into the potential mechanisms of COVID-19 damage to the nervous system in children, and the long-term neurological prognosis of these children requires long-term follow-up.Keywords: COVID-19, Febrile seizures, Children, Nervous system Introduction As the global health landscape is constantly changing, the COVID-19 pandemic has brought unprecedented challenges to human beings [1, 2]. As a special group, children also face many health problems in this epidemic. Febrile seizure (FS) is one of the common emergencies in childhood, with diverse clinical manifestations and complex pathogenesis [3]. In the United States and Western Europe, the prevalence of FS ranges from 2 to 5%, while in Japan, it ranges from 6 to 9% [4–6]. There are differences between the Asian countries that report the incidence of FS and higher, ranging from 1 to 14% [6]. Previous studies on FS mainly focused on the etiology, clinical characteristics and treatment in the non-COVID-19 context. However, with the global pandemic of COVID-19, people have begun to pay attention to whether COVID-19 will have an impact on the occurrence, development, and clinical and biochemical characteristics of FS [7]. Recent studies from the United States [7], South Korea [8], and Japan [9] have shown an association between COVID-19 and an increased incidence of FS in children. It has been reported that COVID-19 may directly invade the central nervous system or cause abnormalities in the nervous system through an inflammatory response mediated by a cytokine storm [10]. Studies have shown that the incidence of abnormal electroencephalogram in children infected with COVID-19 increases significantly, and COVID-19 may affect the nervous system, causing encephalitis, encephalopathy, and seizures [11, 12]. Exploring whether COVID-19 has a specific effect on the clinical and biochemical features of FS is critical for the development of clinical treatment and prevention strategies. However, there are relatively few comparative studies on the clinical and biochemical characteristics of FS in children with COVID-19 and non-COVID-19. Therefore, this study aims to systematically analyze the clinical data of FS children with COVID-19 and non-COVID-19, and compare the differences in clinical features, hematological characteristics and cerebrospinal fluid characteristics between the two groups, in order to provide a basis for clinicians to better understand and treat these two types of children. It also provides a new perspective for further exploring the impact of COVID-19 on the nervous system of children. Method Study design and participants This was a retrospective case–control study. We collected medical records of COVID-19 FS and non-COVID-19 FS in children under 14 years old in Xiamen Children’s Hospital from December 2022 to December 2023. The case group was children with COVID-19 FS, and the control group was children with non-COVID-19 FS. The International League against Epilepsy defines FS as seizures caused by high fever (over 38℃) but without previous neonatal seizures, central nervous system infection, inflammation, or acute systemic metabolic abnormalities that can induce seizures [13]. Children with central nervous system infections, chronic neurodevelopmental problems, underlying epilepsy, or epilepsy due to other cerebral disorders were excluded. Data collection The demographic and clinical data of the case group and the control group were collected by consulting the hospital’s electronic medical record system, including age, gender, length of hospital stay, peak body temperature, presence or absence of other viral infections, relevant laboratory hematological data and cerebrospinal fluid data after admission. The detection method of COVID-19 was to use 2019 novel coronavirus (ORF1ab/N gene) nucleic acid detection kit (double fluorescence PCR) after collecting throat swab specimens. For other viruses, nasal swabs were obtained and tested for the presence of the virus by means of real-time polymerase chain reaction (RT-PCR). Laboratory hematologic tests and other viral tests were performed immediately after admission, usually within 1 h. After ruling out intracranial hemorrhage, cerebrospinal fluid were collected before antibiotic treatment. Data analysis SPSS 21.0 was used to analyze the data. The measurement data in accordance with normal distribution were represented by the mean ± standard deviation (x ± s). The skewed distribution was represented by the median and interquartile range (P 50 (P 25, P 75)). Count data were expressed as frequency (n) and percentage (%). In univariate analysis, the measurement data between the groups was typically distributed using the t-test, and the non-parametric rank sum test was used for skewed distribution. Count data were expressed as the number of cases or constituent ratio (%), and the chi-square test or Fisher exact probability method was used. Variables with statistically significant differences (P < 0.05) were entered into multivariate analysis. In multivariate analysis, binary logistic regression was used, with the presence or absence of FS of COVID-19 as the dependent variable and each indicator as the independent variable. Result General information Fifty COVID-19 children with FS and 192 non-COVID-19 children with FS were enrolled in this study. The median age of the COVID-19 group was 3.72 years, including 37 males (74.00%) and 13 females (26.00%), the median length of hospital stay was 4.5 days and the mean peak temperature was 38.8℃. The median age of the non-COVID-19 group was 2.16 years, including 108 males (56.25%) and 84 females (43.75%), the median length of hospital stay was 4 days and the mean peak temperature was 38.5℃. Univariate analysis showed that age, gender and peak temperature were statistically different between the two groups (P < 0.05). Table 1 summarizes the demographic characteristics of the study population. Table 1The demographic characteristics of the patientsCategoriesCOVID-19 FS group (N = 50)Non-COVID-19 FS group (N = 192)P valueAge (years)3.72 (2.75, 4.73)2.16 (0.38, 5.99)0.007GenderFemale13 (26.00%)84 (43.75%)0.024Male37 (74.00%)108 (56.25%)Length of stay4.5 (3, 6)4 (3, 7)0.757Peak temperature (℃)38.83 ± 0.5738.53 ± 0.51 < 0.001 The demographic characteristics of the patients Co-infection with other viruses The results of this study showed that metapneumovirus infection was statistically different between the COVID-19 group and the non-COVID-19 group of FS. The results as shown in Table 2. Table 2Co-infection with other viruses of the patientsCategoriesCOVID-19 FS group (N = 50)Non-COVID-19 FS group (N = 192)P valueInfluenza A virusnegative501850.350positive07Seasonal H3N2 virusnegative501920.210positive00Influenza B virusnegative501830.793positive09Parainfluenza virusnegative491910.502positive11Coronavirusnegative501900.793positive02Respiratory syncytial virusnegative491910.481positive11Rhinovirusnegative491850.892positive17Bocavirusnegative491900.502positive12Human metapneumovirusnegative471910.029positive31Adenovirusnegative491890.606positive13Mycoplasma pneumoniaenegative491880.724positive14 Co-infection with other viruses of the patients Laboratory tests The relevant laboratory test values for the COVID-19 FS group and the non-COVID-19 FS group were shown in Table 3. Univariate analysis showed that there were statistically significant differences in white blood cell count, red blood cell count, neutrophil count, platelet count, C-reactive protein (CRP), phosphorus, chloride, calcium, potassium, magnesium, lactate dehydrogenase, glutamyl transpeptidase, aspartate aminotransferase, alanine aminotransferase, phosphocreatine kinase, albumin, urea nitrogen and creatinine between the two groups. Table 3The laboratory tests of the patientsCategoriesCOVID-19 FS group (N = 50)Non-COVID-19 FS group (N = 192)P valueWBC(10^9/L)8.96 ± 2.428.06 ± 2.680.033RBC(10^12/L)4.58 (4.30, 4.77)4.37 (4.11, 4.68)0.012Eosinophils(10^9/L)0.12 (0.09, 0.17)0.13 (0.06, 0.20)0.752Basophilic granulocyte(10^9/L)0.02 (0.02, 0.03)0.03 (0.02, 0.04)0.106Monocyte(10^9/L)0.94 ± 0.290.93 ± 0.410.936Neutrophile granulocyte(10^9/L)4.78 (3.14, 5.80)3.62 ± 2.10 < 0.001Lymphocyte(10^9/L)2.93 ± 1.083.28 (1.96, 4.22)0.311PLT(10^9/L)260.80 ± 56.86286.00 (233.25, 359.50)0.019HGB(g/L)121.78 ± 8.05118.69 (112.05, 127.88)0.169CRP(mg/L)4.26 (1.78, 6.98)2.27 (0.71, 6.42)0.016Phosphorus(mmol/L)1.56 (1.44, 1.58)1.59 (1.47, 1.59)0.014Chlorine(mmol/L)102.59 ± 1.73103.12 (102.94, 103.79) < 0.001Calcium(mmol/L)9.48 (9.27, 9.73)9.36 (9.17, 9.40)0.001Sodium(mmol/L)136.63 (136.26, 137.73)136.84 (136.66, 137.44)0.320Potassium(mmol/L)4.09 ± 0.264.19 (3.95, 4.19)0.044Magnesium(mmol/L)0.85 (0.78, 0.86)0.89 (0.86, 0.91) < 0.001Lactic dehydrogenase(U/L)305.82 ± 43.35324.43 (279.48, 368.70)0.035Glutamyl transpeptidase(U/L)11.14 (9.83, 14.03)15.20 (11.00, 31.00) < 0.001Glutamic oxalacetic transaminase(U/L)39.50 (35.36, 44.25)44.00 (34.40, 59.48)0.011Glutamic-pyruvic transaminase(U/L)18.25 (14.00, 23.00)24.00 (16.53, 40.23) < 0.001Creatine kinase isoenzyme(U/L)30.38 (25.94, 36.66)33.69 ± 15.340.696Creatine phosphate kinase(U/L)180.30 (138.83, 268.00)152.25 (107.75, 199.75)0.001Alkaline phosphatase(U/L)209.22 ± 42.88214.42 (165.25, 269.75)0.365Glucose(mmol/L)5.84 (5.58, 6.21)5.86 (5.71, 5.91)0.294Albumin(g/L)43.17 ± 2.1639.75 (37.80, 41.99) < 0.001Globulin(g/L)23.97 (21.60, 26.50)25.32 ± 5.350.245Blood urea nitrogen(mmol/L)3.96 ± 0.864.03 (4.03, 4.03)0.027Creatinine(umol/L)32.05 (26.65, 39.43)28.15 (23.90, 35.43)0.011 The laboratory tests of the patients Independent correlation factors for febrile seizures in children with COVID-19 The variables with statistically significant differences (P < 0.05) after univariate analysis were included in multivariate analysis. The results showed that age, magnesium, albumin, urea nitrogen, and platelet count were independent related factors for the difference between COVID-19 FS and non-COVID-19 FS. Among them, age (OR = 0.715, P = 0.031), blood urea nitrogen (OR = 0.454, P = 0.029), platelet count (OR = 0.987, P = 0.009), and magnesium (OR = 0.109, P < 0.001) were negatively correlated factors, indicating that these were at lower levels in children with COVID-19 FS. Albumin (OR = 1.840, P < 0.001) was a positive correlation factor, indicating that albumin was at a high level in children with COVID-19 FS. The results were shown in Table 4. Table 4Multivariate analysis of influencing factors for FS in children with COVID-19CategoriesBWald chi-squareP valueExp (B)EXP(B) 95% C.Ilower limitupper limitAge-0.3364.6500.0310.7150.5270.970Gender-1.1003.0860.0790.3330.0981.136Peak temperature-0.0110.0660.7970.9890.9111.074Human metapneumovirus2.6231.7920.18113.7820.296641.696Phosphorus-1.1150.3740.5410.3280.00911.716Chlorine0.0110.0530.8191.0110.9201.112Calcium1.5982.2320.1354.9440.60840.238Potassium0.7900.4010.5262.2040.19125.400Magnesium-20.10418.132 < 0.0010.1090.12620.231Lactic dehydrogenase0.0010.0270.8691.0010.9901.012Glutamyl transpeptidase0.0050.0520.8191.0050.9661.044Glutamic oxalacetic transaminase-0.0511.0480.3060.9500.8621.048Glutamic-pyruvic transaminase-0.0621.8330.1760.9400.8601.028Creatine phosphate kinase0.0021.1320.2871.0020.9981.005Albumin0.61016.662 < 0.0011.8401.3732.465Blood urea nitrogen-0.7904.7680.0290.4540.2230.922Creatinine0.0020.0010.9721.0020.9161.095WBC0.1000.1400.7081.1050.6551.865RBC0.6911.5030.2201.9960.6616.029Neutrophile0.4652.2800.1311.5920.8712.909PLT-0.0136.8590.0090.9870.9780.997CRP0.0090.0520.8201.0090.9361.088 Multivariate analysis of influencing factors for FS in children with COVID-19 Comparison of cerebrospinal fluid parameters As shown in Table 5, the medians of cerebrospinal fluid protein, chloride, potassium, sodium, lactate dehydrogenase, and micro-total protein (MTP) of children with FS without COVID-19 were 0.15 g/L, 122.00 mmol/L, 2.70 mmol/L, 142.45 mmol/L, 15.00U/L, and 0.21 g/L. COVID-19 children with FS were 0.18 g/L, 123.05 mmol/L, 2.65 mmol/L, 143.40 mmol/L, 19.00U/L and 0.44 g/L. The results showed statistical differences between the two groups in the four indexes of cerebrospinal fluid protein, potassium, sodium, and MTP. Table 5Cerebrospinal fluid parameters of the patientsCategoriesNon-COVID-19 FS group (N = 45)COVID-19 FS group (N = 27)P valueCerebrospinal fluid protein0.15 (0.12, 0.20)0.18 (0.15, 0.50)0.002Chlorine122.00 (120.80, 125.05)123.05 (120.90, 124.80)0.573Potassium2.70 (2.70, 2.70)2.65 (2.65, 2.65) < 0.001Sodium142.45 (142.45, 142.45)143.40 (143.40, 143.40) < 0.001Lactic dehydrogenase15.00 (12.00, 20.00)19.00 (13.00, 25.00)0.078MTP0.21 (0.15, 0.21)0.44 (0.17, 0.44)0.001 Cerebrospinal fluid parameters of the patients The variables with statistically significant differences (P < 0.05) after univariate analysis were included in the multivariate analysis. As shown in Table 6, potassium and sodium in cerebrospinal fluid were independent factors associated with the difference between COVID-19 FS and non-COVID-19 FS. Potassium (OR = 0.334, P = 0.012) was a negatively correlated factor, indicating a lower level in COVID-19 FS. Sodium (OR = 4.383, P = 0.022) was a positively correlated factor, indicating a high level in COVID-19 FS. Table 6Multivariate analysis of cerebrospinal fluid data of FS in children with COVID-19CategoriesBWald chi-squareP valueExp (B)EXP(B) 95% C.Ilower limitupper limitCerebrospinal fluid protein0.0330.0020.9641.0330.2514.250Potassium-38.53116.5570.0120.3340.12413.223Sodium1.4785.2090.0224.3831.23215.590MTP6.3513.3810.066572.9690.658498931.971 Multivariate analysis of cerebrospinal fluid data of FS in children with COVID-19 Discussion Several studies have shown that COVID-19 infection is significantly associated with an increase in the overall incidence of FS [14, 15]. A South African study found that 20% of 139 children under the age of 13 admitted to hospital with COVID-19 had seizures [16]. A study in Sweden also found that four children with COVID-19 experienced seizures in just one week [17]. The main mechanism by which COVID-19 causes a series of nervous system symptoms is that it invades host cells by binding to angiotensin-converting enzyme 2 and is expressed on the surface of various nerve cells [18], leading to seizures, headache, paralysis, and other symptoms [19]. However, the severity of neurological sequelae of COVID-19 may need to be studied long enough to be explored in depth. By identifying differences in the clinical features of seizures in children caused by COVID-19, it may be crucial to elucidate the pathophysiology and potential possibilities of COVID-19 damage to the central nervous system in the future. Consistent with the Swedish study, boys were more likely to have seizures regardless of COVID-19 infection [17]. However, the sample size was too small to assert a gender preference in the occurrence of COVID-19 seizures, and the results of this study may help to test this idea. In this study, we found that children with COVID-19 FS were younger than those with non-COVID-19 FS [20, 21]. Younger children have immature brain development, higher neuronal excitability, lower blood–brain barrier integrity, and lower tolerance to external stimulation. They are more susceptible to nervous system damage caused by viral infection and increase the risk of seizures. This study found that blood urea nitrogen was lower in children with COVID-19 FS. Urea nitrogen is the end product of protein metabolism in the body, and its level reflects the state of protein metabolism in the body [22]. Urea nitrogen can inhibit glutamate receptor activity, reduce neuronal excitability, and may affect the permeability of the blood–brain barrier, limiting the entry of neurotoxic substances into the central nervous system, thereby helping to maintain the homeostasis of the central nervous system and reducing the risk of convulsion [22]. This is in order to investigate the pathophysiology of FS and further provide a new perspective. The results of this study showed that children with COVID-19 FS had higher albumin levels. As a harmful acute-phase protein, the increase of albumin usually reflects some degree of inflammation. Inflammatory mediators may act directly on the central nervous system, increasing seizure susceptibility [23]. This study showed that children with COVID-19 FS had a low platelet level. Platelets are essential in neurotransmitter release and vasoconstriction processes, and their abnormalities may affect neuronal excitability [24]. Platelets are also involved in regulating the inflammatory response, and their reduction may aggravate the central nervous system damage caused by COVID-19 [25]. Electrolyte imbalances that may affect the neurotransmitter release and conduction cause neuronal excitability change, thus inducing seizure [26, 27]. This study showed that the decrease of potassium ion concentration and the increase of sodium ion concentration in cerebrospinal fluid were independent related factors for FS in COVID-19. Potassium imbalance can cause changes in neuronal membrane potential, enhance excitability, and induce seizures [28]. Sodium imbalance can lead to cellular edema, cause neuronal dysfunction, and increase susceptibility to seizures [29, 30]. Studies have shown that the electrolyte level of cerebrospinal fluid can more directly reflect the pathological changes of the central nervous system and are critical biological markers of FS [31]. Therefore, cerebrospinal fluid electrolyte indicators may be superior to hematological indicators in predicting and explaining the occurrence of FS, which also provides an essential basis for the study of the pathogenesis of COVID-19 FS and formulation of prevention and treatment strategies. Our study also has some limitations. First, we had limited data on the cerebrospinal fluid, which was obtained only when there was clinical suspicion of intracranial infection. Second, since this study was conducted after the COVID-19 prevention and control policy was opened in China during the Omicron period, the results may be inconsistent for other variants. Finally, as it was a retrospective study, the data collected were limited and lacked more specific descriptions such as duration of seizures. The sample size can be expanded and more detailed reports of FS data can be added in the future, and perhaps more surprising findings can be obtained. Conclusion In conclusion, this study provides valuable insights into the underlying mechanisms of neurological damage caused by COVID-19 in children. Compared with non-COVID-19 FS, younger age, lower blood urea nitrogen, platelet, magnesium and higher albumin levels are the unique characteristics of FS in COVID-19 patients. Lower potassium and higher magnesium are the unique characteristics of cerebrospinal fluid in COVID-19 FS. In the future, further studies are needed to elucidate the underlying mechanisms associated with FS in COVID-19 patients, and continuous follow-up of such patients is needed to verify their neurological effects. Acknowledgements Not applicable. Abbreviations Febrile seizures Micro-total protein C-reactive protein Authors’ contributions NXZ and RMY conceived and designed the article. Administrative support was provided by XHH and DYZ. NXZ, RMY, XHH, and DYZ provided study materials or patients. NXZ, RMY, FYL, DL, and YL collected and assembled the data. WTL and GHW analyzed and interpreted the data. All authors contributed to writing and final approval of the manuscript. Funding Fujian Provincial Health Commission science and technology plan project (No. 2022TG027), Xiamen Natural Science Foundation Project (No. 3502Z202373137), Key Program of the Xiamen Medical and Health (No. 3502Z20234013), The Innovation and Entrepreneurship Project for High-level Talents in Medical and Health Fields of Quanzhou Science and Technology Bureau (No. 2023C014YR), Construction of Clinical Key Discipline in Xiamen Children’s Hospital (No. XE2022-YNPY-A03). Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Ethics Committee of Xiamen Children’s Hospital. This study was a retrospective study, and the Ethics Committee of Xiamen Children’s Hospital waived the requirement of informed consent and removed all identifying information to protect patient confidentiality. This study was conducted in accordance with the Declaration of Helsinki and local institutional standards. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Nanxi Zhu and Ruming Ye are joint first authors. Nanxi Zhu and Ruming Ye contributed equally to this work. Contributor Information Deyi Zhuang, Email: zhuangdy526@163.com. Xianghui Huang, Email: xmhxh2013@163.com. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.